Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and <i>RAS</i> Mutations

Juan C. Hernandez‐Prera, Pablo Valderrábano, Jordan H. Creed, Janis V. de la Iglesia, Robbert J.C. Slebos, Barbara A. Centeno, Valentina Tarasova, Julie Hallanger‐Johnson, Colleen Veloski, Kristen J. Otto,

Thyroid · 2020 · 29 citations · 43 references

DOIFull text

Open access

Concepts

Abstract

Background: RAS gene family mutations are the most prevalent in thyroid nodules with indeterminate cytology and are present in a wide spectrum of histological diagnoses. We evaluated differentially expressed genes and signaling pathways across the histological/clinical spectrum of RAS -mutant nodules to determine key molecular determinants associated with a high risk of malignancy. Methods: Sixty-one thyroid nodules with RAS mutations were identified. Based on the histological diagnosis and biological behavior, the nodules were grouped into five categories indicating their degree of malignancy: non-neoplastic appearance, benign neoplasm, indeterminate malignant potential, low-risk cancer, or high-risk cancer. Gene expression profiles of these nodules were determined using the NanoString PanCancer Pathways and IO 360 Panels, and Angiopoietin-2 level was determined by immunohistochemical staining. Results: The analysis of differentially expressed genes using the five categories as supervising parameters unearthed a significant correlation between the degree of malignancy and genes involved in cell cycle and apoptosis ( BAX , CCNE2 , CDKN2A , CDKN2B , CHEK1 , E2F1 , GSK3B , NFKB1 , and PRKAR2A ), PI3K pathway ( CCNE2 , CSF3 , GSKB3 , NFKB1 , PPP2R2C , and SGK2 ), and stromal factors ( ANGPT2 and DLL4 ). The expression of Angiopoietin-2 by immunohistochemistry also showed the same trend of increasing expression from non-neoplastic appearance to high-risk cancer ( p &lt; 0.0001). Conclusions: The gene expression analysis of RAS -mutant thyroid nodules suggests increasing upregulation of key oncogenic pathways depending on their degree of malignancy and supports the concept of a stepwise progression. The utility of ANGPT2 expression as a potential diagnostic biomarker warrants further evaluation.

References

43